Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CD274 negative
Gene Variant Detail

CD274 negative (loss of function)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT04356729 Phase II Atezolizumab + Bevacizumab A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma Recruiting USA 0
NCT04837209 Phase II Dostarlimab-gxly + Niraparib Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer (NADiR) Recruiting USA 0
NCT04683679 Phase II Olaparib + Pembrolizumab Pembrolizumab A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer Recruiting USA 0
NCT04429542 Phase I BCA101 BCA101 + Pembrolizumab Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors Recruiting USA | CAN | AUS 0
NCT04468061 Phase II Sacituzumab govitecan-hziy Pembrolizumab + Sacituzumab govitecan-hziy Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC Recruiting USA 0
NCT05491226 Phase II Axatilimab + Pembrolizumab Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation Recruiting USA 0